Nutlin-3

Catalog No.S1061

Nutlin-3 Chemical Structure

Molecular Weight(MW): 581.5

Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with IC50 of 90 nM in a cell-free assay; stabilizes p73 in p53-deficient cells.

Size Price Stock Quantity  
In DMSO USD 185 In stock
USD 110 In stock
USD 170 In stock
USD 370 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 12 Publications

5 Customer Reviews

  •  

    p53 activation in A76T p53-mutated UKF-NB-3’RITA(10 uM) IV cells. Cells were treated with RITA (10 uM) or nutlin-3 (10 uM) for 24 h and investigated by western blot for the expression of p53 target genes

    Cell Death Dis 2012 3, e294. Nutlin-3 purchased from Selleck.

    Caspase 3/7 activation in UKF-NB-3 or UKF-NB-3rNutlin10 μM cells treated nutlin-3 (10 μM), VCR (10 ng/ml), DOX (20 ng/ml), or CDDP (1000 ng/ml).

    Cell Death Dis 2011 2, e243. Nutlin-3 purchased from Selleck.

  • J Cell Physiol, 2018, 233(9):7424-7434. Nutlin-3 purchased from Selleck.

    Ubiquitination of p53 in vivo by BIRC6 in the presence of Nutlin-3. Cells were treated with Nutlin-3 (20 uM, 24 h) before harvest. Cell lysates were immunoprecipitated with anti-p53 antibody and immunoblotted by anti-ubiquitin antibody.

    Int J Oncol 2014 44, 761-8. Nutlin-3 purchased from Selleck.

  • d qPCR evaluation of DKK1 in MSCs exposed to melphalan in combination with increasing concentrations of nutlin-3 for 24 h. Cells were pre-treated with nutlin-3 for 20 min prior to chemotherapy. *Indicates p value<0.05, One-way ANOVA with Holm-Sidak post hoc

    Med Oncol, 2016, 33(10):113. Nutlin-3 purchased from Selleck.

Purity & Quality Control

Choose Selective Mdm2 Inhibitors

Biological Activity

Description Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with IC50 of 90 nM in a cell-free assay; stabilizes p73 in p53-deficient cells.
Targets
Mdm2 [5]
(Cell-free assay)
180 nM
In vitro

Nutlin-3 potently inhibits the MDM2-p53 interaction, leading to the activation of the p53 pathway. Nutlin-3 treatment induces the expression of MDM2 and p21, and displays potent antiproliferative activity with IC50 of ~1.5 μM, only in cells with wild-type p53 such as HCT116, RKO and SJSA-1, but not in the mutant p53 cell lines SW480 and MDA-MB-435. In SJSA-1 cells, Nutlin-3 treatment at 10 μM for 48 hours significantly induces caspase-dependent cell apoptosis by ~45%. Although Nutlin-3 also inhibits the growth and viability of human skin (1043SK) and mouse embryo (NIH/3T3) with IC50 of 2.2 μM and 1.3 μM, respectively, cells remain viable 1 week post-treatment even at 10 μM of Nutlin-3, in contrast with the SJSA-1 cells with viability lost at 3 μM of Nutlin-3 treatment. [1] Nutlin-3 does not induce the phosphorylation of p53 on key serine residues and reveals no difference in their sequence-specific DNA binding and ability to transactivate p53 target genes compared with phosphorylated p53 induced by the genotoxic drugs doxorubicin and etoposide, demonstrating that phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. [2] Although binding less efficiently to MDMX than to MDM2, Nutlin-3 can block the MDMX–p53 interaction and induce the p53 pathway in retinoblastoma cells (Weri1) with IC50 of 0.7 μM. [3] Nutlin-3 at 30 μM also disrupts endogenous p73-HDM2 interaction and enhances the stability and proapoptotic activities of p73, leading to the dose-dependent cell growth inhibition and apoptosis induction in cells without wild-type p53. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF7 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XrU|XDqM7:TR?= MYO0POKhcA>? MnG0Zoxw[2u|IEK3MW9JSy2rbnT1Z4VlKGOnbHygdJJwdGmoZYLheIlwdiClb33wZZJi[mynIITvJJRp[XRib3[gZoF{[WxibHX2[Yx{ MXeyOlM2ODV4NR?=
NP69 NITmT45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPHNllKSzVyPUOxMlY6yrF{LkW0JO69VQ>? NInkRmozPjJ3MkW3OS=>
NP460 M3zPNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF:3RlZKSzVyPUKyMlg2yrFzLkG4JO69VQ>? M3LWZlI3OjV{NUe1
C666-1 M1LSS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTF7Lkm1xtE5Njl|IN88US=> NX7QdGs5OjZ{NUK1O|U>
C666-1 MY\D[YxtKF[rYXLpcIl1gSCDc4PhfS=> NVLsXoh{OTBiwsXN Mo\YOFghcA>? NGfEOpNFVVOR MWXz[Y5{cXSrenXzJGM3PjZvMTDj[YxteyC2bzD0bIUh[3m2b4TvfIlkKGWoZnXjeEBw\iClaYPwcIF1cW5? NXnkNlh3OjZ{NUK1O|U>
C666-1  NFHvZYFHfW6ldHnvckBCe3OjeR?= MX[xNEDDvU1? MXGyOEBp MWHEUXNQ M3npUoFkfGm4YYTld{B1cGVicEWzJJBifGi5YYmsJJVxemWpdXzheIlv\yCyNUOsJJAzOSCjbnSgUYRuOg>? NYnUeY9ZOjZ{NUK1O|U>
C666-1 NHzSTnpCeG:ydH;zbZMhSXO|YYm= MUWxNEDDvU1? Mnj0OFgwPzJiaB?= NIn5WpRFVVOR MV;z[Y5{cXSrenXzJGM3PjZvMTDj[YxteyC2bzDjbZNxdGG2aX6tbY5lfWOnZDDhdI9xfG:|aYO= NGTDcoczPjJ3MkW3OS=>
A549 M4j6bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnCfIVLOjRiaB?= MXHJR|UxRTF5Lk[4JOKyKDRwNUKg{txO NVjoT3JvOjZzMkWyN|A>
A549-NTC Ml7GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PRVVI1KGh? MWrJR|UxRTF7LkSyJOKyKDFwOU[g{txO NES2T3UzPjF{NUKzNC=>
A549-920 M37Bc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHuOVMzPCCq Mlv1TWM2OD1|Mz64OUDDuSB2Lki0JO69VQ>? Mnr4NlYyOjV{M{C=
CRL-5908 MlLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\rV3pPOjRiaB?= M4\QXmlEPTB;M{iuO|EhyrFiMj60N{DPxE1? NV7HVWhVOjZzMkWyN|A>
L6 MkPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHflPHYyOMLizszNxsA> M4S0fVI1NzR6L{eyJIg> NFK5R4FFVVOR MkXsbY5pcWKrdIOgZ4VtdHNicILvcIln\XKjdHnvckBidmRiZHnm[oVz\W62aXH0bY9v M3HCT|I2QDdzN{m0
C2C12 M2fY[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\sT3JmOTEEoN88UeKh MX6yOE81QC95MjDo M{f5RmROW09? MnvabY5pcWKrdIOgZ4VtdHNicILvcIln\XKjdHnvckBidmRiZHnm[oVz\W62aXH0bY9v NF\6doszPTh5MUe5OC=>
MCF-7  Mlj1SpVv[3Srb36gRZN{[Xl? NGX0TG8yOMLizszN Mly4SG1UVw>? NWL5UG1McW6qaXLpeJMh[3mlbHnuJGQyKGGwZDDEbYNmesLi NEW3O4ozPTdyMkewNy=>
DU4475  M3m5[mZ2dmO2aX;uJGF{e2G7 M{fXcVUwOTBxMkCg{txO NYLn[ohUOjUEoHi= NUPhcppy\G:5boLl[5Vt[XSnczDUc4NiNTFiZH;z[UBl\XCnbnTlcpRtgQ>? NW[0cGoxOjV3NEexO|Q>
SMMC-7721 MWrGeY5kfGmxbjDBd5NigQ>? NH[1XXoyOCEQvF2= NFrzVXE1QCCq MoWySG1UVw>? MoSyZ4F2e2W|IFTORUBFW0JiZHHtZYdm MmS1NlU2PDR|NkG=
SMMC-7721 MmLoSpVv[3Srb36gRZN{[Xl? MVqxNEDPxE1? NXGxcFl{PDhiaB?= NYfyeZY6TE2VTx?= M3HHb4lv\HWlZYOgeIhmKGOqcn;tZZRqdi2kb4Xu[EBxem:2ZXnuJGlHUTF4IITvJJBienSrYXzsfUBtd2OjbHn6[UBqdiC2aHWgZ5l1d3CuYYPtxsA> NYrpZ5FTOjV3NESzOlE>
SMMC-7721 Ml;kSpVv[3Srb36gRZN{[Xl? Mn7kNVAh|ryP NVjs[29lPDhiaB?= NHzIfIRFVVOR NHn3eYNqdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3dCpGlHVkJzwrDtVm5C MXyyOVU1PDN4MR?=
SMMC-7721 NULJeWRqTnWwY4Tpc44hSXO|YYm= MV[xNEDPxE1? NY\nUnl7OzZiaB?= MWrEUXNQ NEHTb2hk[XW|ZYOgeIhmKGWldH;wbYMh\XiycnXzd4lwdiCxZjDJSmkyPg>? NITLZ2wzPTV2NEO2NS=>
MCF-7 NVTrNIpXTnWwY4Tpc44hSXO|YYm= MlLyNVDDqM7:TR?= MV2wMVI1KGh? MYDpcoR2[2W|IIC1N{BidmRicEKxM2NqeDF? MluyNlU1QDJ|N{O=
OVCAR10 NYHHeoJDTnWwY4Tpc44hSXO|YYm= MYSxNOKh|ryP MVKyNYjDqA>? MVvEUXNQ M{i0T4lv[3KnYYPld{BxPTNicILveIVqdiCuZY\lcJM> M33XVFI2PDJ4NUS4
NCI-H23 NUjKdlZLTnWwY4Tpc44hSXO|YYm= NXjxcXk{OTEEoN88US=> NY[wSG8xOjGqwrC= NIj2XXpFVVOR MXnpcoNz\WG|ZYOgdFU{KHC{b4TlbY4hdGW4ZXzz MYCyOVQzPjV2OB?=
A2780 NGTDbm5HfW6ldHnvckBCe3OjeR?= NVP6T4VGOTEEoN88US=> MYqyNYjDqA>? MkP1SG1UVw>? MYPpcoNz\WG|ZYOgdFU{KHC{b4TlbY4hdGW4ZXzz MWCyOVQzPjV2OB?=
NCI-H23 NEXlZoZHfW6ldHnvckBCe3OjeR?= NFTST2YyOMLizszN MVGyNYjDqA>? MWPEUXNQ M3PhXoRm[3KnYYPld{B1cGViRn;4UVEhdGW4ZXzz MWKyOVQzPjV2OB?=
A2780 MmXTSpVv[3Srb36gRZN{[Xl? NILOTZYyOMLizszN NETFUnQzOWkEoB?= MlHSSG1UVw>? NFzROWFl\WO{ZXHz[ZMhfGinIF\vfG0yKGyndnXsdy=> M3rmRlI2PDJ4NUS4
HCT116  MmnxSpVv[3Srb36gRZN{[Xl? NYXEPXBiOTBiwsXN NYH5V5JlOjRiaB?= NGPxeY9k[XW|ZYOgZUBxPTNvZHXw[Y5l\W62IITleJJieGyxaXSgS|Eu[XK{ZYP0JIlvKGSrcHzvbYQhUEOWMUG2JINtd26nczDEN{BidmRiREi= M2LVeFI2OzhyMEW1
MCF-10CA1a NHjwOW5HfW6ldHnvckBCe3OjeR?= NV3tVYpwOTEEoN88US=> MmLhOFghcA>? NHfNb2lFVVOR M{jjSYlvcGmkaYTzJIJie2GuIHnueoF{cW:wIHHu[EBz\WS3Y3XkJHRITi4QskOtbY5lfWOnZDDpcpZie2mxbjD0c{Bj[XOjbDDs[ZZmdHN? NWTSW2FuOjV{NUe3Nlk>
MCF-10A1  NIXtOnFHfW6ldHnvckBCe3OjeR?= NXnoXJA5OTEEoN88US=> NEfWXm4zPC92ODDo NFvxWnpFVVOR M4rx[YlvcGmkaYTzJI1q\3KjdHnvckBw\iCwb4LtZYwh[nKnYYP0JIVxcXSqZXzpZYzDqA>? MoLhNlUzPTd5Mkm=
MCF-10CA1a NVfQRoNnTnWwY4Tpc44hSXO|YYm= MX6xNOKh|ryP NILsT4szPCCq NGqyO4JFVVOR NHrjS4xl\WO{ZXHz[ZMhfGinIGTHSk3PujNvaX7keYNm\CCvUl7BJIxmfmWuczDv[m1OWDJuwrDNUXA6NCCjbnVCpIlvfGWpcnnuxsDPusLiMx?= NVnBWGlkOjV{NUe3Nlk>
MCF-10CA1a MYHGeY5kfGmxbjDBd5NigQ>? MnXqNVDDqM7:TR?= NGXkbYMzPCCq MoXKSG1UVw>? MkHsbY5pcWKrdIOgJHRITi4QskOtbY5lfWOnZDDFVGhDOsLibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:w MXeyOVI2Pzd{OR?=
SK-BR-7 NEjnNGNHfW6ldHnvckBCe3OjeR?= Ml7ONVDDqM7:TR?= NF\CVpIzPCCq NXz3OpM4TE2VTx?= NHK0UZdqdmirYnn0d{AhXEeILd8yN{1qdmS3Y3XkJGVRUEJ{wrDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36= NID0dmYzPTJ3N{eyPS=>
SUM102PT M{\NT2Z2dmO2aX;uJGF{e2G7 MVGxNOKh|ryP MUKyOEBp NX7LZpRRTE2VTx?= NHWz[5pqdmirYnn0d{AhXEeILd8yN{1qdmS3Y3XkJGVRUEJ{wrDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36= MX[yOVI2Pzd{OR?=
RAW 264.7 NGDhWoRHfW6ldHnvckBCe3OjeR?= M3zseVExyqEQvF2= NIr2N|Q{OCCvaX6= NEjtTZhxemW4ZX70d{B1cGVicEWzJJJm\HWldHnvckBqdiC{ZYPwc45{\SC2bzDMVHM> MUKyOVE4OjV2Nx?=
RAW 264.7 M1O2fmZ2dmO2aX;uJGF{e2G7 MojqNVDDqM7:TR?= NEfsdFQ{OCCvaX6= M2\E[JJm\HWlZYOgeIhmKEySUz3heYdu\W62ZXSgeIhmKE6ILd86RkBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZYN1cX[rdIm= MkjmNlUyPzJ3NEe=
RAW 264.7 MXfGeY5kfGmxbjDBd5NigQ>? M1jBSVExyqEQvF2= M3nXVFMxKG2rbh?= NXfNZYF[cW6qaXLpeJMhVFCVLXnu[JVk\WRiTl:gdJJw\HWldHnvcuKh M4rwb|I2OTd{NUS3
MCF7  MlPlR4VtdCCYaXHibYxqfHliQYPzZZk> NFK0dmszNjViwsXN Ml3vOUBl Ml\hSG1UVw>? M2juOpNmdnOrdHn6[ZMhVUOINzD0c{BRSVKSIHnubIljcXSrb36= M3rxSVI2ODh3OUCy
MCF7  MnPpSpVv[3Srb36gRZN{[Xl? NYnZdpRLOi53INM1US=> Mo\uOFghcA>? NYjVSpFtTE2VTx?= NX60UlBP\GWlcnXhd4V{KHSqZTDoc41wdG:pb4XzJGRUSiC{ZYDhbZIh\nKncYXlcoNq\XN? MXmyOVA5PTlyMh?=
ACHN MlXYR4VtdCCYaXHibYxqfHliQYPzZZk> M13rSFAvPS1zMDFOwG0> M1zqdVAuPiCm NULSSFVuTE2VTx?= NF75THJqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M3TScFI2ODZ5N{i3
Caki-2 MX;D[YxtKF[rYXLpcIl1gSCDc4PhfS=> M1TCeFAvPS1zMDFOwG0> MnSzNE03KGR? NXHiOWFlTE2VTx?= Mn[wbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NIrs[FYzPTB4N{e4Oy=>
A498 MULD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MVOwMlUuOTBizszN NWfI[45EOC14IHS= Mn\tSG1UVw>? M1TY[olvcGmkaYTzJJBzd2yrZnXyZZRqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MkX5NlUxPjd5OEe=
115 MnPXR4VtdCCYaXHibYxqfHliQYPzZZk> MmDHNE42NTFyIN88US=> MmrWNE03KGR? M3Tkc2ROW09? NHHPVWlqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M1X2d|I2ODZ5N{i3
117 M1HKXGNmdGxiVnnhZoltcXS7IFHzd4F6 M4XKdlAvPS1zMDFOwG0> NIDuSW4xNTZiZB?= M2TxZmROW09? MlfUbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MVWyOVA3Pzd6Nx?=
ACHN M3XEcmZ2dmO2aX;uJGF{e2G7 Mn75NE42NzFxNTFOwG0> MlK5OFghcA>? NH7meVlFVVOR MVrs[YFleyC2bzDpcoNz\WG|ZXSg[ZhxemW|c3nvckBw\iCyNUOgZY5lKHOxbXWgdFU{KHSjcnfleEBo\W6nc{qgUWROOixiYX7kJJAzOQ>? NWGzbm9GOjVyNke3PFc>
Caki-2 NInWW2hHfW6ldHnvckBCe3OjeR?= MViwMlUwOS93IN88US=> MUS0PEBp NGn3[VJFVVOR MV7s[YFleyC2bzDpcoNz\WG|ZXSg[ZhxemW|c3nvckBw\iCyNUOgZY5lKHOxbXWgdFU{KHSjcnfleEBo\W6nc{qgUWROOixiYX7kJJAzOQ>? M3HST|I2ODZ5N{i3
A498 NXHq[pBTTnWwY4Tpc44hSXO|YYm= NXWwfHNxOC53L{GvOUDPxE1? Ml6xOFghcA>? M4eyemROW09? MYDs[YFleyC2bzDpcoNz\WG|ZXSg[ZhxemW|c3nvckBw\iCyNUOgZY5lKHOxbXWgdFU{KHSjcnfleEBo\W6nc{qgUWROOixiYX7kJJAzOQ>? MoH4NlUxPjd5OEe=
115 MWXGeY5kfGmxbjDBd5NigQ>? NEPFZo4xNjVxMT:1JO69VQ>? NHnEN2o1QCCq NFO2UldFVVOR M3TLZYxm[WS|IITvJIlv[3KnYYPl[EBmgHC{ZYPzbY9vKG:oIIC1N{BidmRic3;t[UBxPTNidHHy[4V1KGenbnXzPkBOTE1{LDDhcoQheDJz M{T4ZlI2ODZ5N{i3
ACHN M3q4TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjQ[oI4PSEQvF2= MXy0PEBp Mmn1SG1UVw>? M12xVolv\HWlZYOgZ4VtdCCleXPs[UBienKnc4VCpC=> NISy[GszPTB4N{e4Oy=>
Caki-2 Mlu1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHoNJczPSEQvF2= NX;YWoNEPDhiaB?= NEfIeIVFVVOR NWLxWlJncW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeOKh NUnmflF{OjVyNke3PFc>
A498 NHH1e|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLrXFQ2KM7:TR?= NIe2V281QCCq NYP5U|NLTE2VTx?= NXezdnRFcW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeOKh NFLYenEzPTB4N{e4Oy=>
115 M{nJU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvVU4RzPSEQvF2= NFXle3A1QCCq NH3QcHNFVVOR NUXZU4pncW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeOKh NV3D[VJWOjVyNke3PFc>
ACHN NIHYZYdHfW6ldHnvckBCe3OjeR?= MmDHOUDPxE1? MVK0PEBp M3LYdWROW09? NXjXXId2cW6mdXPld{BxPTNvZHXw[Y5l\W62IIPlcoV{[2WwY3ZCpC=> MkX1NlUxPjd5OEe=
Caki-2 NGDEe45HfW6ldHnvckBCe3OjeR?= MYi1JO69VQ>? NFzFNYk1QCCq MkH1SG1UVw>? Mn3lbY5lfWOnczDwOVMu\GWyZX7k[Y51KHOnbnXzZ4Vv[2YEoB?= Mn3VNlUxPjd5OEe=
A498 M1PPVWZ2dmO2aX;uJGF{e2G7 NV7sUZN{PSEQvF2= MljGOFghcA>? MlHJSG1UVw>? MkHJbY5lfWOnczDwOVMu\GWyZX7k[Y51KHOnbnXzZ4Vv[2YEoB?= NWrH[VFZOjVyNke3PFc>
115 M4TLbGZ2dmO2aX;uJGF{e2G7 NX3HbHl7PSEQvF2= NWftOIpIPDhiaB?= MoHSSG1UVw>? MmXLbY5lfWOnczDwOVMu\GWyZX7k[Y51KHOnbnXzZ4Vv[2YEoB?= Mn\UNlUxPjd5OEe=
MOLM-13 MmHLSpVv[3Srb36gRZN{[Xl? NFjwSI83yqEQvF2= MYqwMVghcA>? M{KzXmROW09? MYrpcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\iCyNUOsJG1FVTJuIICyNUBidmRiYXPleJlt[XSnZDDwOVM> NEjRfnAzPDh6NUC4Ni=>
MOLM-13 Mmn1SpVv[3Srb36gRZN{[Xl? NIjxemw3yqEQvF2= MmDhOkBp M4[5Z2ROW09? NHzRVpVmdmijbnPld{B1cGViYXPleJlt[XSrb36gc4YhcGm|dH;u[UBJOkJiYX7kJIhm[XRic3jvZ4sheHKxdHXpcpMhUHOyMkegZY5lKEi|cEmw NHn6PJgzPDh6NUC4Ni=>
HepG2 M4GyXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIS4SGY4OiCq NVXMfYQ4TE2VTx?= M3HlfWlEPTB;M{WuPFYhyrFiMj65JO69VQ>? M2nSd|I1QDh2OEC5
HepG2/As NXX0NGFkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYG3NkBp NHmzSYtFVVOR NUjlTGFjUUN3ME22PE4yOyEEsTC5MlYh|ryP MUeyOFg5PDhyOR?=
SMMC7721 NVLzTHA3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTSO|IhcA>? M4rWVWROW09? NGnXT3dKSzVyPUOxMlI5KMLzIESuNkDPxE1? NGDjepAzPDh6NEiwPS=>
SMMC7721/Ac MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYi3NkBp MWLEUXNQ MX;JR|UxRTV3LkKxJOKyKDVwMEOg{txO M1LaOFI1QDh2OEC5
Huh-7 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;xNZV[PzJiaB?= NUPKVXNITE2VTx?= NUPwO3NoUUN3ME2zN{46PiEEsTCzMlkh|ryP MXWyOFg5PDhyOR?=
Hep3B NHKxbmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYewfI5QPzJiaB?= NE\6NpZFVVOR M2K3c2lEPTB;MkCuNVghyrFiMT64OEDPxE1? MYiyOFg5PDhyOR?=
HepG2 NVjIOVBmSXCxcITvd4l{KEG|c3H5 M{nDfolv\HWlZYOgZZBweHSxc3nz MYiyOFg5PDhyOR?=
SMMC7721 NIOwTZdCeG:ydH;zbZMhSXO|YYm= MlHobY5lfWOnczDhdI9xfG:|aYO= M2PZWlI1QDh2OEC5
Huh-7 MnjZRZBweHSxc3nzJGF{e2G7 NEfrXWdqdmS3Y3XzJIFxd3C2b4Ppdy=> M37mWFI1QDh2OEC5
Hep3B NV\sN5N[SXCxcITvd4l{KEG|c3H5 NUj5T4p6cW6mdXPld{BieG:ydH;zbZM> MX:yOFg5PDhyOR?=
U2OS  NXPRZZBuTnWwY4Tpc44hSXO|YYm= NUS3fXljOjBizszN MWqyOEBp MnW4bY5kemWjc3XzJJRp\SCvUl7BJIxmfmWuczDv[uKhSkOOMlGxMEBDS0y[TNMgZY5lSkOOVx?= MojENlQ5Pjd{NUm=
AML2 NEDuUllCeG:ydH;zbZMhSXO|YYm= MWiyM|ExKM7:TR?= MnK5NlQwPDhiaB?= NHLsZVJqdmS3Y3XzJIFxd3C2b4Ppdy=> NX7rSYp6OjR4NUm3OFk>
MOML13 NHPxZ4NCeG:ydH;zbZMhSXO|YYm= M4\DVFIwOTBizszN MnSzNlQwPDhiaB?= M{\4UIlv\HWlZYOgZZBweHSxc3nz M3zBe|I1PjV7N{S5
AML2 MXLGeY5kfGmxbjDBd5NigQ>? M2PKWFEx|ryP NUT5WZliOi92IHi= MlTMbY5kemWjc3XzJJRp\SCuZY\lcEBw\iCyNUO= MV[yOFY2QTd2OR?=
AML3 NGHXSoVHfW6ldHnvckBCe3OjeR?= M4XzWFEx|ryP NWC4TZh5Oi92IHi= MkHFbY5kemWjc3XzJJRp\SCuZY\lcEBw\iCyNUO= M{PBS|I1PjV7N{S5
MOML13 MnWwSpVv[3Srb36gRZN{[Xl? MmDmNVDPxE1? NIPMZ2ozNzRiaB?= M1\mfIlv[3KnYYPld{B1cGVibHX2[Ywhd2ZicEWz MXyyOFY2QTd2OR?=
BeWo NV3YOnNiTnWwY4Tpc44hSXO|YYm= MXSzNEDDvU1? M4fz[FI1KGh? NEjVPGRqdmO{ZXHz[ZMheDV|LDDN[I0zNCCyMkGgZY5lKFC3bXGgZZQhfGinIIDyc5RmcW5ibHX2[Yw> MnP0NlQ1QThzNUS=
BeWo MlvKRZBweHSxc3nzJGF{e2G7 MV2zNEDDvU1? M4rDW|I1KGh? NYrPdWY3cW6lcnXhd4V{KGGyb4D0c5Nqew>? NUfVfY1DOjR2OUixOVQ>
OCI MoHjSpVv[3Srb36gRZN{[Xl? NW\5Zow2OTBizszN NH3NPJAzPCCq M{K3dJVxemWpdXzheIV{KHSqZTDTU2NUNTFiZYjwdoV{e2mxbh?= MlXnNlQ1PzN3NkK=
MOLM M2i4[mZ2dmO2aX;uJGF{e2G7 M2fYUVExKM7:TR?= NHTjcIszPCCq M1PvPJVxemWpdXzheIV{KHSqZTDTU2NUNTFiZYjwdoV{e2mxbh?= MUSyOFQ4OzV4Mh?=
U2OS  NHzXb2tHfW6ldHnvckBCe3OjeR?= M3fXRVIxKM7:TR?= NHHrb5EzPCCq NHzBUINqdmO{ZXHz[ZMhfGinIHzleoVteyCxZjD0bIUhUE9vMTDwdo91\WmwIHHzJJdmdGxiYYOgeIhmKHB3MzDwdo91\Wmw NVPYVnBlOjR|Nk[wNFc>
RKO M{LmT2Z2dmO2aX;uJGF{e2G7 MkDHNlAh|ryP M2fZVVI1KGh? M1\qOolv[3KnYYPld{B1cGVibHX2[Yx{KG:oIITo[UBJVy1zIIDyc5RmcW5iYYOge4VtdCCjczD0bIUheDV|IIDyc5RmcW5? MV2yOFM3PjByNx?=
U2OS  NULRcWl{TnWwY4Tpc44hSXO|YYm= MXeyNEDPxE1? MlzuNlQhcA>? M33TcYlv\HWlZYOgTG8uOSCneIDy[ZN{cW:wIHH0JJRp\SCuZY\lcEBw\iC2cnHud4NzcXC2aX;u NXnqeGhlOjR|Nk[wNFc>
RKO NHjmV45HfW6ldHnvckBCe3OjeR?= Mmr2NlAh|ryP NHGyTnAzPCCq M2LlWolv\HWlZYOgTG8uOSCneIDy[ZN{cW:wIHH0JJRp\SCuZY\lcEBw\iC2cnHud4NzcXC2aX;u MUeyOFM3PjByNx?=
SMMC-7721  NU\NOGdGS2WubDDWbYFjcWyrdImgRZN{[Xl? NHPiR44yNjJ3LUKwJO69VQ>? NXThOW5JOjRxNEivO|IhcA>? NIPCW3pFVVOR MmPKbY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJIRwe2ViYX7kJJRqdWViZHXw[Y5l\W62bIm= MmjzNlQzQDZ|MUK=
HuH-7 M1P5TmNmdGxiVnnhZoltcXS7IFHzd4F6 NFfqXokyNjJ3LUKwJO69VQ>? M33tVVI1NzR6L{eyJIg> NH7JS5NFVVOR NXTHPYVQcW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKGSxc3WgZY5lKHSrbXWg[IVx\W6mZX70cJk> MXSyOFI5PjNzMh?=
SMMC-7721  MVnBdI9xfG:|aYOgRZN{[Xl? MViyNEDPxE1? NYfLUWdZPDhiaB?= NEn5W2tFVVOR MYXpcoR2[2W|IHHwc5B1d3Orcx?= M3fsPFI1Ojh4M{Gy
HuH-7 MkHERZBweHSxc3nzJGF{e2G7 MmDkNlAh|ryP NV3MdHROPDhiaB?= NWXJV4FoTE2VTx?= NGK5Z4FqdmS3Y3XzJIFxd3C2b4Ppdy=> MWWyOFI5PjNzMh?=
SMMC-7721  MnXFSpVv[3Srb36gRZN{[Xl? NH\LTGUyOCEQvF2= Mo\zN|YhcA>? MXfEUXNQ M3iyd4Rwf25vcnXneYxifGW|IITo[UBxem:2ZXnuJIV5eHKnc4Ppc44hdGW4ZXygc4YheGixc4Doc{1U\XJ|OUKtdFU{ MYWyOFI5PjNzMh?=
HuH-7 NY\YSo1pTnWwY4Tpc44hSXO|YYm= NX\IeHdOOTBizszN MnLQN|YhcA>? MVXEUXNQ M4j1XoRwf25vcnXneYxifGW|IITo[UBxem:2ZXnuJIV5eHKnc4Ppc44hdGW4ZXygc4YheGixc4Doc{1U\XJ|OUKtdFU{ NWm2eG1wOjR{OE[zNVI>
AT2 NF61UIRHfW6ldHnvckBCe3OjeR?= Mnf2OU8yOCEQvF2= NVfUS|d{dGWjZIOgeI8h[SC|dXLzeIFvfGmjbDDhZ4N2dXWuYYTpc44hd2ZidHjlJJA2OyCycn;0[YlvKGG|IIflcIwh[XNidHjlJIV5eHKnc4Ppc44hd2ZiaYTzJIRqemWldDD0ZZJo\XS|IICyNUwhVUSPMjDhcoQhfGinIIDyc{1ieG:ydH;0bYMhSkG[IHHu[EBRXU2DIIDyc5RmcW6|wrC= M1L2ZlI1OjRyMkCz
REH MXXGeY5kfGmxbjDBd5NigQ>? NH\PRYM2NzFyIN88US=> M1ixd4xm[WS|IITvJIEhe3Wkc4ThcpRq[WxiYXPjeY12dGG2aX;uJI9nKHSqZTDwOVMheHKxdHXpckBieyC5ZXzsJIF{KHSqZTDlfJBz\XO|aX;uJI9nKGm2czDkbZJm[3RidHHy[4V1eyCyMkGsJG1FVTJiYX7kJJRp\SCycn:tZZBweHSxdHnjJGJCYCCjbnSgVHVOSSCycn;0[Ylve8Li M2jsb|I1OjRyMkCz
UoCB6 NIT5eXhHfW6ldHnvckBCe3OjeR?= MXy1M|ExKM7:TR?= NGfYfZJt\WGmczD0c{BiKHO3YoP0ZY51cWGuIHHjZ5VufWyjdHnvckBw\iC2aHWgdFU{KHC{b4TlbY4h[XNid3XscEBieyC2aHWg[ZhxemW|c3nvckBw\iCrdIOg[Ilz\WO2IIThdodmfHNicEKxMEBOTE1{IHHu[EB1cGVicILvMYFxd3C2b4TpZ{BDSVhiYX7kJHBWVUFicILveIVqdnQEoB?= MUiyOFI1ODJyMx?=
AT2 M2TuNmNmdGxiVnnhZoltcXS7IFHzd4F6 MlHGNE0zPSEQvF2= MmfFbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? MUSyOFI1ODJyMx?=
REH M2HH[2NmdGxiVnnhZoltcXS7IFHzd4F6 MnHNNE0zPSEQvF2= NHvXZ4pqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 MWSyOFI1ODJyMx?=
UoCB6 M3rDWmNmdGxiVnnhZoltcXS7IFHzd4F6 MUGwMVI2KM7:TR?= M4rTVYlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? MX:yOFI1ODJyMx?=
A2780 NVm4W25MTnWwY4Tpc44hSXO|YYm= NEm1Xm42NzFyL{KwJO69VQ>? M4TBdFI1KGh? MnfyeZBz\We3bHH0[ZMheDV|LDDNSG0zNCCyMkGgZY5lKESUNTDwdo91\WmwIHzleoVteyCmb4PlJIRmeGWwZHXueIx6yqB? MXqyOFE{PjF2Nx?=
H460 NIG2c2tHfW6ldHnvckBCe3OjeR?= MoPQOU8yOC9{MDFOwG0> NX\wXIQ5OjRiaB?= NHHwPJl2eHKnZ4XsZZRmeyCyNUOsJG1FVTJuIICyNUBidmRiRGK1JJBzd3SnaX6gcIV3\Wy|IHTvd4Uh\GWyZX7k[Y51dHoEoB?= M1P2WlI1OTN4MUS3
Lovo  NHHVOGFHfW6ldHnvckBCe3OjeR?= NX7yXlVrPS9zMD:yNEDPxE1? NYrTe4d{OjRiaB?= M3v1fpVxemWpdXzheIV{KHB3MzygUWROOixicEKxJIFv\CCGUkWgdJJwfGWrbjDs[ZZmdHNiZH;z[UBl\XCnbnTlcpRtgcLi MUOyOFE{PjF2Nx?=
A2780 MYjBdI9xfG:|aYOgRZN{[Xl? NGfCfFE2NzFyL{KwJO69VQ>? NYTnTJZqOjRiaB?= NX\pWVk1\W6qYX7j[ZMh[XCxcITvd4l{KGmwZIXjeIlwdiCkeTDENlY6UC:HMUm1VkBwfmW{IILoWHJCUUx? MYiyOFE{PjF2Nx?=
H460 MlvpRZBweHSxc3nzJGF{e2G7 MkLkOU8yOC9{MDFOwG0> NF\NSoUzPCCq MYLlcohidmOnczDhdI9xfG:|aYOgbY5lfWO2aX;uJIJ6KER{NknIM2UyQTWUIH;2[ZIhemiWUlHJUC=> NHXLNYozPDF|NkG0Oy=>
Lovo  MWDBdI9xfG:|aYOgRZN{[Xl? M3jTSFUwOTBxMkCg{txO MlziNlQhcA>? NUHrTYdK\W6qYX7j[ZMh[XCxcITvd4l{KGmwZIXjeIlwdiCkeTDENlY6UC:HMUm1VkBwfmW{IILoWHJCUUx? MYGyOFE{PjF2Nx?=

... Click to View More Cell Line Experimental Data

In vivo Oral administration of Nutlin-3 at 200 mg/kg twice daily for 3 weeks significantly inhibits the tumor growth of SJAS-1 xenografts by 90%, comparable with the effect of doxorubicin treatment with 81% inhibition of tumor growth. [1]

Protocol

Kinase Assay:

[1]

+ Expand

Biacore study:

Competition assay is performed on a Biacore S51. A Series S Sensor chip CM5 is utilized for the immobilization of a PentaHis antibody for capture of the His-tagged p53. The level of capture is ~200 response units (1 response unit corresponds to 1 pg of protein per mm2). The concentration of MDM2 protein is kept constant at 300 nM. Nutlin-3 is dissolved in DMSO at 10 mM and further diluted to make a concentration series of Nutlin-3 in each MDM2 test sample. The assay is run at 25 °C in running buffer (10 mM Hepes, 0.15 M NaCl, 2% DMSO). MDM2-p53 binding in the presence of Nutlin-3 is calculated as a percentage of binding in the absence of Nutlin-3 and IC50 is calculate
Cell Research:

[1]

+ Expand
  • Cell lines: HCT116, RKO, SJSA-1, SW480, and MDA-MB-435
  • Concentrations: Dissolved in DMSO, final concentrations ~ 30 μM
  • Incubation Time: 8, 24, and 48 hours
  • Method:

    Cells are exposed to various concentrations of Nutlin-3 for 8, 24 and 48 hours. The transcriptional levels of p21 and MDM2 genes are analyzed by real-time PCR, and protein levels by western blotting. Cell viability is measured by the MTT assay. Cell apoptosis is determined by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL) staining with flow cytometry and fluorescence microscopy.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Athymic female nude mice (Nu/Nu-nuBR) injected subcutaneously with SJSA-1 cells
  • Formulation: Formulated in 2% Klucel, 0.5% Tween 80
  • Dosages: 200 mg/kg
  • Administration: Orally, twice a day
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (171.96 mM)
Ethanol 30 mg/mL (51.59 mM)
Water Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 581.5
Formula

C30H30Cl2N4O4

CAS No. 890090-75-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is this a racemic mixture of Nutlin-3a and Nutlin-3b or just the Nutlin-3a enantiomer?

  • Answer:

    It is a racemate.

Mdm2 Signaling Pathway Map

Related Mdm2 Products0

Tags: buy Nutlin-3 | Nutlin-3 supplier | purchase Nutlin-3 | Nutlin-3 cost | Nutlin-3 manufacturer | order Nutlin-3 | Nutlin-3 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID